Iovance shares soar after Q2 revenue beat

Iovance Biotherapeutics shares jumped about 37% to more than a one-year high of $5.95 after the company posted second-quarter revenue of $99.3 million, beating analysts' estimate of $87.83 million, according to LSEG data.

CEO Frederick Vogt said that based on second-quarter performance and strong demand trends, the company is reviewing its previously issued 2026 revenue forecast of $350 million to $370 million and will provide an update during the third quarter.

Quarterly net loss per share narrowed to 11 cents from a loss of 33 cents a year ago.

As of June 30, 2026, Iovance's cash position was about $304 million, and current cash is expected to fund operations into the second half of 2028.

The stock is up 116% year to date.